Treatment of knee osteoarthritis with intra-articular injection of allogeneic adipose-derived stem cells (ADSCs) ELIXCYTE®: a phase I/II, randomized, active-control, single-blind, multiple-center clinical trial.
Chen CF., Hu CC., Wu CT., Wu HH., Chang CS., Hung YP.
Clinical Trial with a reported sample of 64 on Knee Osteoarthritis, Osteoarthritis, published in Stem Cell Res Ther (2021) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Stem Cell Res Ther (2021)
- Country
- England
- Reported sample size
- 64
- Source database
- PubMed
- PMID
- 34717765
- PMCID
- PMC8557559
- DOI
- 10.1186/s13287-021-02631-z
- NCT
- NCT02784964
- Citations
- 75
Abstract (original English)
Objective To evaluate the safety and efficacy of intra-articular (IA) injection of allogeneic adipose-derived stem cells (ADSCs) ELIXCYTE® for knee osteoarthritis. Methods This was a patient-blind, randomized, active-control trial consisted of 4 arms including hyaluronic acid (HA) control and 3 ELIXCYTE® doses. A total of 64 subjects were screened, and 57 subjects were randomized. The primary endpoints included the changes from baseline to post-treatment visit of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at Week 24 and the incidence of adverse events (AEs) and serious adverse events (SAEs). Results No ELIXCYTE®-related serious adverse events were reported during 96 weeks of follow-up and no suspected unexpected serious adverse reaction (SUSAR) or death was reported. The changes of the primary endpoint, WOMAC pain score at Week 24, showed significant differences in all ELIXCYTE® groups, as well as in HA groups between post-treatment visit and baseline. The ELIXCYTE® groups revealed significant decreases at Week 4 compared to HA group in WOMAC total scores, stiffness scores, functional limitation scores suggested the potential of ELIXCYTE® in earlier onset compared to those from HA. The significant differences of visual analog scale (VAS) pain score and Knee Society Clinical Rating System (KSCRS) functional activities score at Week 48 after
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisPubMed
Clinical Outcomes of Biologic Therapies for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Studies With ≥12-Month Follow-up.
Meta-analysis on Knee Osteoarthritis, Osteoarthritis, published in Mod Rheumatol (2026) — summary generated from the PubMed abstract.
- 2026
Mod Rheumatol - Level AMeta-analysisEurope PMC
Towards optimized rehabilitation with regenerative therapy: A systematic review and meta-analysis on the effects of cell-based injections for knee osteoarthritis
Meta-analysis on Knee Osteoarthritis, Osteoarthritis, published in Knee Surg Sports Traumatol Arthrosc (2026) — summary generated from the PubMed abstract.
- 2026
Knee Surg Sports Traumatol Arthrosc - Level ASystematic ReviewPubMed
Intra-articular fat grafting for pain relief and functioning improvement in patients with knee osteoarthritis: systematic review.
Systematic Review on Knee Osteoarthritis, Osteoarthritis, published in Disabil Rehabil (2026) — summary generated from the PubMed abstract.
- 2026
Disabil Rehabil - Level ASystematic ReviewPubMed
Research Landscape of Stem Cell Applications in Musculoskeletal Tissue: A Scoping Review.
Systematic Review on Knee Osteoarthritis, Osteoarthritis, published in Cells (2026) — summary generated from the PubMed abstract.
- 2026
Cells - Level AMeta-analysisPubMed
Comparative efficacy of different doses of mesenchymal stem cells derived from different tissue sources for knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials.
Meta-analysis with a reported sample of 602 on Knee Osteoarthritis, Osteoarthritis, Chronic Inflammation, Immune Modulation, published in PeerJ (2026) — summary generated from the PubMed abstract.
- 2026
- n = 602
PeerJ - Level AMeta-analysisEurope PMC
Influence of platelet-rich plasma composition on pain and functional performance in knee osteoarthritis: a systematic review and network meta-analysis
Meta-analysis with a reported sample of 5251 on Knee Osteoarthritis, Osteoarthritis, published in Knee Surg Relat Res (2026) — summary generated from the PubMed abstract.
- 2026
- n = 5251
Knee Surg Relat Res